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component.
Methods: Polymeric PEA microspheres were prepared and loaded with
VEGF. The release of VEGF from these microspheres, in both cell culture
medium and human serum at 37C was followed over time. VEGF con-
centrations were analyzed by ELISA; biological activity of the released VEGF
was assessed using proliferation assays on human umbilical vein endo-
thelial cells (HUVECs). VEGF-loaded microspheres were investigated for
their pro-angiogenic potential in vivo, either in matrigel plugs or by
intramuscular injection after induction of hindlimb ischemia in mice.
Neovascularization was monitored by immunohistochemistry and Laser
Doppler Perfusion Imaging.
Results: Our experiments showed that VEGF remains stable and bio-
logically active during both fabrication and long-term storage of the mi-
crospheres. After re-suspension in either cell culture medium or human
serum, VEGF is released from the microspheres. An initial burst release
over 48 hours is followed by a gradual, sustained release over 2 weeks. The
released VEGF was able to induce proliferation of HUVECs with virtually no
loss of biological activity. In vivo, microspheres containing approximately
15 ng VEGF were able to induced angiogenesis similar to 250 ng of un-
protected VEGF in a matrigel plug assay in mice. After induction of hindlimb
ischemia, both VEGF and VEGF-loaded microspheres show a comparable
increase in blood ﬂow recovery. Immunohistochemical analyses however
show a stronger increase in the number of collateral arteries in the
adductor muscles of mice treated with VEGF loaded microspheres
compared to free VEGF.
Conclusion: VEGF can be loaded into polymeric PEA microspheres and
stored without loss of biological activity. Under physiological conditions, a
burst of VEGF is released over 48 hours, followed by sustained release of
VEGF over 2 weeks. VEGF-loaded microspheres showed an over tenfold
increase in angiogenic potential compared to free VEGF in vivo in matrigel
plugs. Furthermore the increase in number of collateral arteries in the
adductor muscles of mice subjected to hindlimb ischemia suggests a
beneﬁcial effect of sustained release of VEGF.
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Introduction: As options for open surgery in the treatment of great
saphenous vein (GSV) reﬂux, both UGFS (ultrasound guided foam sclero-
therapy) and EVLA (endovenous laser) have been used for years, but the
long-term results compared to open surgery are still unclear. In the current
study we analyzed the 5 year results of a RCT comparing UGFS, EVLA and
Surgery in the treatment of GSV reﬂux and varicose veins.
Methods: We randomized 233 patients from 2 hospitals who had
symptomatic GSV reﬂux in one leg for UGFS, EVLA or open surgery (ligating
and stripping the GSV). In total 196 patients from our hospital were
included and treated during 2008e2010. In EVLA and Surgery groups local
phlebectomies were done simultaneously when necessary. 5 years after the
treatment we invited all patients treated in our hospital to clinical control.
Prevalence of varicose veins, DD-ultrasound and patient satisfaction were
evaluated. Furthermore, information on the additional treatments for the
same leg during the follow up was recorded. 166 patients (UGFS n ¼ 68,
EVLA n ¼ 67, Surgery n ¼ 61) participated in the 5 year control (85% of the
patients originally treated in our hospital).
Results: After 5 years from UGFS, EVLA and Surgery, there was no reﬂux
in GSV DD in 50.8%, 89.5% and 95.9% respectively (UGFS vs. EVLA/Surgery
p < 0.01). The CEAP classiﬁcation was not signiﬁcantly associated with the
type of treatment, and neither was cosmetic satisfaction, experienced pain
caused by the varicosities, disability or the presence of oedema. However,
during the 5 year period 15.3% of the patients in the UGFS group had
gotten additional treatment (most often laser ablation of GSV and local
phlebectomies) compared to EVLA and Surgery groups (3.3% and 4.0%
respectively, p < 0.05 compared to UGFS-group). Furthermore, at 5 yearfollow, 22.0% of the patients in the UGFS group were assigned for addi-
tional treatment compared to 6.8% in EVLA group and 8.0% in Surgery
group (p < 0.05). The odds of needing a new treatment were 5.9 times
higher if treated with UGFS compared to EVLA, EVLA having the lowest
ratio of new treatment.
Conclusion: Even though there was no difference in subjective patient
satisfaction, UGFS resulted in more additional treatments and was asso-
ciated with signiﬁcantly more fully or partially reﬂuxing GSV’s after the
treatment. Therefore, we conclude that UGFS is not as feasible as EVLA or
open surgery.
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Introduction: Chronic venous disease (CVD) is a common and potentially
costly condition affecting a signiﬁcant proportion of the population. This
pilot randomised control trial investigates the effect of a neuromuscular
electrical stimulation (NMES) device that causes sequential contraction of
the foot and calf muscles in patients with CVD.
Methods: Twenty-two patients with CEAP C2-C4 venous disease
were randomised to a sham or test device. Patients were asked to use
the device for 30 minutes per day for 6 weeks. Haemodynamic mea-
surements (duplex ultrasound and laser doppler ﬂuximetry), limb vol-
ume (perometer), venous reﬁll time (digital photoplethysmography) and
quality of life outcome measures were measured at baseline and after 6
weeks.
Results: The mean age of participants was 62 years, BMI 28.6, with a
15:7 female preponderance. At week 0, there was a signiﬁcant improve-
ment in femoral vein haemodynamics (from baseline) whilst using the
device in the test compared to sham group (time averaged mean velocity
(TAMV) 102.4% versus -9.1%, p < 0.0001; volume ﬂow 107.9% versus
-3.7%, p < 0.0001; peak velocity 377.7% versus -6.7%, p < 0.0001). The
sham group demonstrated an increase in limb volume, which was pre-
vented with the use of the device in the test group (sham +2.0%,
p < 0.0001; test +0.8%; p ¼ 0.0623). There was no improvement in limb
volume in either the sham or test group over the 6 weeks (sham +0.7%,
p ¼ 0.16; test +2.3%, p ¼ 0.74). A non-statistically signiﬁcant improvement
in disease speciﬁc quality of life outcome measures (AVVQ) was observed
in the test group over the 6 weeks.
Conclusion: This trial demonstrated a signiﬁcant improvement in venous
haemodynamics and reduction in limb swelling with the test device
compared to the sham group following immediate usage. In addition, it had
a positive effect on quality of life outcome measures. The device is safe to
use as a home based adjunct in managing venous disease. Due to the small
sample size, some improvements were not statistically signiﬁcant and
subgroup analysis was not performed. Further trials are required to
determine optimal frequency of device usage and the effect on different
subgroups of patients with venous disease.
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Introduction: 3 e10% of the worldwide population is suffering from pe-
ripheral arterial disease and 1 e3% will ultimately develop critical limb
ischemia (CLI). In the presence of long lesions, a femorodistal bypass often
is the only option to avoid major amputation and secure a better quality of
life. The angiosome concept divides the foot into six anatomic regions
(angiosomes) fed by distinct source arteries arising from the posterior
tibial, anterior tibial and peroneal arteries. This study investigates whether
bypass to the artery directly feeding the ischemic angiosome has an impact
on wound healing, major amputation rate and mortality before healing was
obtained.
